164332-88-1 Usage
Description
t-boc-N-amido-PEG2-bromide is a PEG (polyethylene glycol) derivative that features a bromide group and a Boc-protected amino group. t-boc-N-amido-PEG2-bromide is characterized by its hydrophilic PEG spacer, which enhances solubility in aqueous environments. The presence of the bromide as a leaving group makes it highly reactive in nucleophilic substitution reactions, while the Boc group can be removed under mild acidic conditions to reveal the free amine.
Uses
Used in Medical Research:
t-boc-N-amido-PEG2-bromide is used as a research tool for the synthesis of various biologically active compounds, including ligands and polypeptides. Its unique structure allows for the creation of graft polymer compounds and new materials, which can be applied in different areas of medical research.
Used in Drug-Release Applications:
In the pharmaceutical industry, t-boc-N-amido-PEG2-bromide serves as a cleavable linker for the synthesis of antibody drug conjugates (ADCs). This application takes advantage of the compound's reactivity and solubility properties to improve the targeted delivery and release of therapeutic agents.
Used in Nanotechnology:
t-boc-N-amido-PEG2-bromide is utilized in nanotechnology for the development of new materials and coatings. Its hydrophilic nature and reactivity contribute to the creation of polyethylene glycol-modified functional coatings, which can have various applications in different industries.
Used in Cell Culture:
t-boc-N-amido-PEG2-bromide is also used in cell culture applications, where its properties can be leveraged to improve the growth and maintenance of cells in vitro, potentially leading to advancements in cell biology and tissue engineering.
Overall, t-boc-N-amido-PEG2-bromide is a versatile compound with applications spanning across medical research, drug delivery, nanotechnology, and cell culture, making it a valuable asset in the development of new materials and therapeutic strategies.
Synthesis
The synthesis of?t-boc-N-amido-PEG2-bromide is as follows:Alcohol 64 (1 .25 g, 6.09 mmol) was dissolved in DCM (34 mL). The solution was cooled to 0°C and methanesulfonyl chloride (MsCI, 0.80 mL, 10.3 mmol, 1 .7 equiv) was added to the solution followed by Et3N (1.9 mL, 13.4 mmol, 2.2 equiv). After stirring for 3 h at rt, the reaction mixture was diluted with acetone (33 mL) and LiBr (8.9 g, 103 mmol, 17 equiv) was added. The reaction mixture was stirred overnight at rt. After that time, the solvents were evaporated under reduced pressure. The crude residue was diluted with EtOAc and washed with H20 and brine. The organic phase was dried over anhyd Na2S04. The suspension was filtered over cotton and the filtrate concentrated in vacuo. Purification by flash chromatography eluting with PE/Acetone (85:15→ 8:2) gave bromide 65 (1 .60 g, 5.95 mmol, 98%) as a colourless oil.
Check Digit Verification of cas no
The CAS Registry Mumber 164332-88-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,4,3,3 and 2 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 164332-88:
(8*1)+(7*6)+(6*4)+(5*3)+(4*3)+(3*2)+(2*8)+(1*8)=131
131 % 10 = 1
So 164332-88-1 is a valid CAS Registry Number.
164332-88-1Relevant articles and documents
Creation of Fluorescent RXR Antagonists Based on CBTF-EE and Application to a Fluorescence Polarization Binding Assay
Takioku, Maho,Takamura, Yuta,Fujihara, Michiko,Watanabe, Masaki,Yamada, Shoya,Kawasaki, Mayu,Ito, Sohei,Nakano, Shogo,Kakuta, Hiroki
, p. 1024 - 1029 (2021)
Retinoid X receptor (RXR) ligands often bind in modes in which the carboxy group forms a hydrogen bond inside the ligand-binding pocket (LBP). However, our previously reported RXR antagonist, CBTF-EE (4a), binds with its carboxy group directed outside the LBP and its alkoxy side chain located inside the LBP. Here, we examined the binding modes of 4b and 4c bearing a nitrobenzoxadiazole (NBD) or boron-dipyrromethene (BODIPY) fluorophore, respectively, at the end of the alkoxy chain of 4a. Both compounds function as RXR antagonists. 4c, but not 4b, was available for a fluorescence polarization binding assay, indicating that rotation of BODIPY, but not NBD, is restricted in the bound state. The fluorescence findings, supported by docking simulations, suggest the fluorophores are located outside the LBP, so that the binding mode of 4b and 4c is different from that of 4a. The assay results were highly correlated with those of a [3H]9-cis-retinoic acid assay.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
-
Page/Page column 484, (2020/03/29)
Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).
CARBOHYDRATE LIGANDS THAT BIND TO ANTIBODIES AGAINST GLYCOEPITOPES OF GLYCOSPHINGOLIPIDS
-
Page/Page column 83; 84, (2017/05/25)
The invention relates to carbohydrate ligands and moieties, respectively, mimicking glycoepitopes comprised by glycosphingolipids of the nervous system, particularly glycoepitopes comprised by glycosphingolipids of the cerebroside, the globoside-, the gan
